Pharming Group N.V. (PHAR)
PHAR Stock Price Chart
Explore Pharming Group N.V. interactive price chart. Choose custom timeframes to analyze PHAR price movements and trends.
PHAR Company Profile
Discover essential business fundamentals and corporate details for Pharming Group N.V. (PHAR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Dec 2020
Employees
404.00
Website
https://www.pharming.comCEO
Fabrice Chouraqui
Description
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Financial Timeline
Browse a chronological timeline of Pharming Group N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 23 Oct 2025
EPS estimate is $0.05.
Earnings released on 31 Jul 2025
EPS came in at $0.06 surpassing the estimated -$0.10 by +160.00%, while revenue for the quarter reached $110.56M , beating expectations by +37.89%.
Earnings released on 8 May 2025
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $86.71M , beating expectations by +19.22%.
Earnings released on 13 Mar 2025
EPS came in at $0.05 falling short of the estimated $0.07 by -28.57%, while revenue for the quarter reached $95.96M , beating expectations by +57.50%.
Earnings released on 24 Oct 2024
EPS came in at -$0.02 falling short of the estimated $0.01 by -300.00%, while revenue for the quarter reached $83.84M , beating expectations by +10.93%.
Earnings released on 1 Aug 2024
EPS came in at -$0.01 falling short of the estimated -$0.00 by -400.00%, while revenue for the quarter reached $79.60M , beating expectations by +10.66%.
Earnings released on 8 May 2024
EPS came in at -$0.19 falling short of the estimated $0.01 by -2.00K%, while revenue for the quarter reached $90.03M , beating expectations by +31.58%.
Earnings released on 14 Mar 2024
EPS came in at -$0.03 falling short of the estimated $0.05 by -160.00%, while revenue for the quarter reached $59.71M , missing expectations by -16.86%.
Earnings released on 26 Oct 2023
EPS came in at $0.05 falling short of the estimated $0.13 by -61.54%, while revenue for the quarter reached $70.32M , beating expectations by +14.02%.
Earnings released on 3 Aug 2023
EPS came in at $0.02 surpassing the estimated -$0.02 by +200.00%, while revenue for the quarter reached $59.89M , beating expectations by +12.51%.
Earnings released on 11 May 2023
EPS came in at -$0.17 falling short of the estimated -$0.01 by -1.60K%, while revenue for the quarter reached $58.84M , beating expectations by +16.87%.
Earnings released on 16 Mar 2023
EPS came in at -$0.19 falling short of the estimated $0.01 by -2.00K%, while revenue for the quarter reached $46.25M , missing expectations by -23.24%.
Earnings released on 27 Oct 2022
EPS came in at $0.01 falling short of the estimated $0.02 by -48.65%, while revenue for the quarter reached $52.97M , missing expectations by -1.00%.
Earnings released on 4 Aug 2022
EPS came in at $0.04 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $52.45M , beating expectations by +0.89%.
Earnings released on 12 May 2022
EPS came in at $0.05 surpassing the estimated -$0.06 by +183.33%, while revenue for the quarter reached $51.86M , beating expectations by +8.85%.
Earnings released on 17 Mar 2022
EPS came in at $0.01 matching the estimated $0.01, while revenue for the quarter reached $51.56M , missing expectations by -10.45%.
Earnings released on 9 Aug 2021
EPS came in at -$0.00 , while revenue for the quarter reached $58.33M .
Earnings released on 7 Apr 2021
EPS came in at $0.02 , while revenue for the quarter reached $86.13M .
Earnings released on 31 Mar 2021
EPS came in at $0.01 , while revenue for the quarter reached $49.70M .
Earnings released on 30 Sept 2020
EPS came in at $0.01 , while revenue for the quarter reached $68.71M .
PHAR Stock Performance
Access detailed PHAR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.